Prospective, randomized, open label comparative study of efficacy of atorvastatin versus atorvastatin with vitamin D3 in patients with dyslipidemia attending tertiary care hospital
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20213228Keywords:
Atorvastatin, Vitamin D3, Dyslipidemia, Lipid profileAbstract
Background: Cardiovascular diseases are one of the most important group of diseases causing premature mortality and morbidity. Dyslipidemia is an independent risk factor for cardiovascular diseases and is a disorder of lipoprotein metabolism. Various research studies support role of vitamin D against dyslipidemia. Vitamin D concentration positively correlates with HDL cholesterol and negatively with serum LDL and triglyceride levels. Vitamin D supplementation to Atorvastatin appeared to have increased cholesterol lowering activity more than either substance did alone.
Methods: The study was conducted in an outpatient department of general medicine for a duration of 12 weeks in a tertiary care hospital. Total of 100 patients with dyslipidemia were selected based on measurement of lipid profile. Out of 100 patients, 50 patients under group A were treated with atorvastatin 10mg and balance 50 patients under group B treated with atorvastatin and Vitamin D3 1000 IU/day orally. Patients were followed up monthly for 3 months and lipid profile was assessed at baseline and at the end of study. The baseline characteristics were similar in both study groups.
Results: On comparing groups at the end of 12 weeks mean LDL, triglycerides and VLDL were significantly reduced in group B than group A with p<0.001. The mean HDL level too increased in group B than group A with p<0.001.
Conclusions: Fasting plasma lipid profile improvement was higher in the atorvastatin with vitamin D3 group compared to atorvastatin group.
References
Fodor G. Primary prevention of CVD: treating dyslipidemia. American Family Physician. 2011;15;83(10):1207
WHO. Cardiovascular disease. Fact sheet no. 317. 2021. Available at: www.who.int/mediacentre/factsheet/fs317/en/index.html. Accessed on 10 Feb 2021.
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1–executive summary. J clin lipidol. 2014;8(5):473-88.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am College Cardiol. 2019;74(10):e177-232.
Abhima MB, Wilson V. A comparative study of effect of Vitamin D and atorvastatin versus atorvastatin alone on serum HDL, VLDL and triglycerides in hyperlipidemic patients. MedPulse Int J Pharmacol. 2020;16(1):15-20.
Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, Dhandania VK et al. Prevalence of dyslipidemia in urban and rural India: the ICMR–INDIAB study. PloS one. 2014;9(5):e96808.
Gupta R, Rao RS, Misra A, Sharma SK. Recent trends in epidemiology of dyslipidemias in India. Indian heart j. 2017;69(3):382-92.
Salo A, Logomarsino JV. Relationship of vitamin D status and cardiometabolic risk factors in children and adolescents. Pediatric endocrinology reviews: PER. 2011;9(1):456-62.
Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Reviews in Endocrine and Metabolic Disorders. 2017;18(2):153-65.
Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch internal med. 2008;168(15):1629-37.
Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, G7oldenberg N et al. Low serum 25 (OH) vitamin D levels (< 32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Translational Res. 2009;153(1):11-6.
Fahrleitner A, Dobnig H, Obernosterer A, Pilger E, Leb G, Weber K et al. Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease. J general internal med. 2002;17(9):663-9.
Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am j cardiol. 2007;99(7):903-5.
Pérez-Castrillón JL, Abad Manteca L, Vega G, Del Pino Montes J, De Luis D, Dueňas Laita A. Vitamin D levels and lipid response to atorvastatin. Int j endocrinol. 2010;19;2010.
Li YC. Vitamin D regulation of the renin–angiotensin system. J cellular biochem. 2003;88(2):327-31.
Zittermann A, Gummert JF, Börgermann J. The role of vitamin D in dyslipidemia and cardiovascular disease. Curr Pharm Des. 2011;17(9):933-42.
Gupta AK, Sexton RC, Rudney H. Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. Journal of lipid research. 1989;30(3):379-86.
Goldstein MR. Myopathy, statins, and vitamin D deficiency. Am J Cardiol. 2007;100(8):1328.
Nimitphong H, Holick MF. Vitamin D status and sun exposure in southeast Asia. Dermatoendocrinol. 2013;5(1):34-7.
Srivastava SK. Drugs for dyslipidaemia (Hyperlipidaemia). In: A complete text book of medical pharmacology. 1st edition. New Delhi, Avichal publishers. 2012;321-40.
Schwartz JB. Effects of vitamin D supplementation in atorvastatin‐treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Therap. 2009;85(2):198-203.
Kazlauskaite R, Powell LH, Mandapakala C, Cursio JF, Avery EF, Calvin J. Vitamin D is associated with atheroprotective high-density lipoprotein profile in postmenopausal women. J Clin Lipidol. 2010;4(2):113-9.
Maki KC, Rubin MR, Wong LG, McManus JF, Jensen CD, Marshall JW et al. Serum 25-hydroxyvitamin D is independently associated with high density lipoprotein cholesterol and the metabolic syndrome in men and women. J Clin Lipidol. 2009;3(4):289-96.
Bersot TP. Drug Therapy for Hypercholesterolemia and Dyslipidemia, in: LaurenceL. Brunton, Bruce A. Chabner, Bjorn C. Knollmann. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 13th edition. New York, Mc Graw Hill. 2011;877-904.
